Inaedis provides a proprietary Room Temperature Aerosol Dehydration (RTAD) platform that converts liquid biologics into room‑temperature‑stable powders or suspensions, preserving activity while eliminating cold‑chain requirements. The technology can be retrofitted to existing cGMP spray‑dryers for continuous, scalable production and supports multiple delivery formats, including ultra‑concentrated subcutaneous injectables, inhalable dry‑powders, and intranasal sprays, enabling non‑invasive, at‑home administration for pharma, public‑health, and defense customers.
Funding
Funding not disclosed
Founders
Product
Problem
Biologic drugs and vaccines are often limited by fragile formulations that require cold‑chain storage, invasive administration routes, and costly, low‑throughput manufacturing processes, restricting patient access and increasing supply‑chain risk.
Solution
Inaedis offers a proprietary Room Temperature Aerosol Dehydration (RTAD) platform that rapidly dehydrates liquid biologics into stable powders or particle suspensions at room temperature without added heat. The technology uses ultra‑fine droplet formation and millisecond‑scale drying, reducing dehydration‑induced damage by 10–100× compared with lyophilization or conventional spray drying. RTAD can be retrofitted onto existing cGMP spray‑dryers, enabling continuous, scalable production with 5–10× capacity gains and a 12–18 month scale‑up validated by digital‑twin modeling. The platform supports multiple drug‑product formats—including ultra‑concentrated subcutaneous injectables (>500 mg/mL), cold‑chain‑free powders, inhalable dry‑powder aerosols, and intranasal sprays—allowing non‑invasive, at‑home administration and global distribution without refrigeration.
Target Audience
Primary customers are pharmaceutical companies, biologics developers, and contract manufacturing organizations seeking scalable, cost‑effective formulation solutions for monoclonal antibodies, vaccines, and other advanced therapeutics, as well as defense and public‑health agencies requiring cold‑chain‑independent medical countermeasures.
Features
- Millisecond‑scale, room‑temperature aerosol dehydration that preserves biological activity and minimizes aggregation
- Compatibility with antibodies, proteins, viral vectors, lipid nanoparticles, and other fragile biologics
- Retrofit integration with existing cGMP spray‑drying equipment, avoiding $50M+ greenfield investments
- Continuous processing with digital‑twin CFD validation for predictable scale‑up and 5–10× manufacturing capacity increase
- Enables ultra‑high concentration formulations (>500 mg/mL) for subcutaneous injection using standard needles or autoinjectors
- Produces room‑temperature‑stable powders for cold‑chain‑free storage, strategic stockpiling, and field deployment
- Generates particles with tunable size for inhaled dry‑powder or intranasal delivery, supporting non‑invasive administration routes